IL319684A - נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם - Google Patents

נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם

Info

Publication number
IL319684A
IL319684A IL319684A IL31968425A IL319684A IL 319684 A IL319684 A IL 319684A IL 319684 A IL319684 A IL 319684A IL 31968425 A IL31968425 A IL 31968425A IL 319684 A IL319684 A IL 319684A
Authority
IL
Israel
Prior art keywords
ccr8
monoclonal antibodies
therapeutic use
therapeutic
monoclonal
Prior art date
Application number
IL319684A
Other languages
English (en)
Original Assignee
Domain Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domain Therapeutics filed Critical Domain Therapeutics
Priority claimed from PCT/EP2023/076155 external-priority patent/WO2024062076A1/en
Publication of IL319684A publication Critical patent/IL319684A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL319684A 2022-09-21 2023-09-21 נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם IL319684A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306389 2022-09-21
PCT/EP2023/076155 WO2024062076A1 (en) 2022-09-21 2023-09-21 Anti-ccr8 monoclonal antibodies and their therapeutic use

Publications (1)

Publication Number Publication Date
IL319684A true IL319684A (he) 2025-05-01

Family

ID=95482473

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319684A IL319684A (he) 2022-09-21 2023-09-21 נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם

Country Status (8)

Country Link
EP (1) EP4590703A1 (he)
JP (1) JP2025531391A (he)
KR (1) KR20250111755A (he)
CN (1) CN120476141A (he)
AU (1) AU2023345469A1 (he)
CA (1) CA3268049A1 (he)
IL (1) IL319684A (he)
MX (1) MX2025003315A (he)

Also Published As

Publication number Publication date
JP2025531391A (ja) 2025-09-19
CN120476141A (zh) 2025-08-12
MX2025003315A (es) 2025-06-02
KR20250111755A (ko) 2025-07-22
CA3268049A1 (en) 2024-03-28
AU2023345469A1 (en) 2025-05-01
EP4590703A1 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
IL319931A (he) נוגדנים אנטי- cd122 ושימושים בהם
IL289488A (he) נוגדנים חד שבטיים הקושרים egfrviii ושימושם
GB202012331D0 (en) Therapeutic antibodies
IL315438A (he) נוגדנים אנטי-cd3 חדשים ושימושים בהם
EP4413044A4 (en) ANTI-CD3 MONOCLONAL ANTIBODIES AND THERAPEUTIC CONSTRUCTS
IL308361A (he) נוגדנים בעלי ספציפיות כפולה ושימושיהם
IL292599A (he) נוגדנים tmem219 ושימושים רפואיים בהם
IL325570A (he) נוגדן כנגד cd3 ושימוש בו
IL317849A (he) נוגדנים חד-שבטיים אנטי- slc34a2ושימושים בהם
IL314622A (he) נוגדנים מואנשים כנגד Nectin-2 ותרופות מצומדות שלהם
IL320972A (he) נוגדנים אנטי-tfr1 ושימושים בהם
IL319684A (he) נוגדנים חד-שבטיים אנטי- ccr8והשימוש הרפואי בהם
IL319678A (he) נוגדנים חד-שבטיים אנטי- ccr8 והשימוש הרפואי בהם
EP4125946A4 (en) MONOCLONAL ANTIBODIES TARGETING HSP70 AND THEIR THERAPEUTIC USES
IL308014A (he) נוגדנים אנטי-גלקטין-9 ושימושים טיפוליים בהם
HK40126953A (en) Anti-ccr8 monoclonal antibodies and their therapeutic use
EP4314054A4 (en) SINGLE-DOMAIN ANTI-EGFR ANTIBODIES AND THERAPEUTIC CONSTRUCTS
GB202204813D0 (en) Human monoclonal antibodies and methods of use thereof
GB202204736D0 (en) Human monoclonal antibodies and methods of use thereof
IL310551A (he) נוגדנים חד-שבטיים ספציפיים ל-osmr ושיטות השימוש בהם
EP4486788A4 (en) ANTI-CD73 ANTIBODIES AND THEIR USES
IL315029A (he) נוגדנים חד-שבטיים אנטי- il-13ra2ושימושים בהם
IL325073A (he) נוגדן אנטי-cd200r1 ושימושים בו
GB202311497D0 (en) Therapeutic antibodies
GB202310818D0 (en) Therapeutic antibodies